Haemonetics Co. (HAE) SVP Sells $150,800.00 in Stock

Haemonetics Co. (NYSE:HAE) SVP Jacqueline Scanlan sold 1,508 shares of Haemonetics stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $100.00, for a total transaction of $150,800.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Jacqueline Scanlan also recently made the following trade(s):

  • On Thursday, March 7th, Jacqueline Scanlan sold 116 shares of Haemonetics stock. The shares were sold at an average price of $83.57, for a total transaction of $9,694.12.

NYSE:HAE traded up $2.32 during trading hours on Thursday, reaching $101.79. The company had a trading volume of 843,888 shares, compared to its average volume of 485,551. The company has a current ratio of 2.44, a quick ratio of 1.62 and a debt-to-equity ratio of 0.48. Haemonetics Co. has a 52 week low of $80.24 and a 52 week high of $117.56. The company has a market cap of $4.82 billion, a PE ratio of 42.77, a price-to-earnings-growth ratio of 2.41 and a beta of 0.85.

Haemonetics (NYSE:HAE) last posted its earnings results on Tuesday, May 7th. The medical instruments supplier reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.06. Haemonetics had a net margin of 5.69% and a return on equity of 18.88%. The business had revenue of $249.30 million during the quarter, compared to the consensus estimate of $250.62 million. During the same quarter in the previous year, the firm posted $0.43 EPS. The firm’s revenue was up 6.7% on a year-over-year basis. Research analysts forecast that Haemonetics Co. will post 2.9 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. grew its position in shares of Haemonetics by 5.9% during the 1st quarter. BlackRock Inc. now owns 6,385,237 shares of the medical instruments supplier’s stock valued at $558,580,000 after acquiring an additional 358,431 shares during the period. Wellington Management Group LLP grew its position in shares of Haemonetics by 20.0% during the 1st quarter. Wellington Management Group LLP now owns 5,935,913 shares of the medical instruments supplier’s stock valued at $519,273,000 after acquiring an additional 988,179 shares during the period. Vanguard Group Inc grew its position in shares of Haemonetics by 1.9% during the 3rd quarter. Vanguard Group Inc now owns 5,619,707 shares of the medical instruments supplier’s stock valued at $643,906,000 after acquiring an additional 107,357 shares during the period. Jackson Square Partners LLC lifted its stake in shares of Haemonetics by 12.8% during the 1st quarter. Jackson Square Partners LLC now owns 1,655,676 shares of the medical instruments supplier’s stock valued at $144,838,000 after buying an additional 187,950 shares in the last quarter. Finally, Neuberger Berman Group LLC lifted its stake in shares of Haemonetics by 14.2% during the 1st quarter. Neuberger Berman Group LLC now owns 1,625,242 shares of the medical instruments supplier’s stock valued at $142,176,000 after buying an additional 202,406 shares in the last quarter. 98.31% of the stock is owned by institutional investors and hedge funds.

HAE has been the subject of several analyst reports. Zacks Investment Research downgraded shares of Haemonetics from a “hold” rating to a “sell” rating in a research report on Thursday, January 24th. Barrington Research reaffirmed an “outperform” rating and issued a $116.00 target price (up previously from $112.00) on shares of Haemonetics in a research report on Wednesday, May 8th. TheStreet raised shares of Haemonetics from a “c+” rating to a “b-” rating in a research report on Tuesday, May 7th. Raymond James raised shares of Haemonetics from a “market perform” rating to an “outperform” rating and set a $110.00 target price for the company in a research report on Tuesday. Finally, ValuEngine downgraded shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 5th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $118.60.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thelincolnianonline.com/2019/05/16/haemonetics-co-hae-svp-sells-150800-00-in-stock.html.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Story: What is the Coverage Ratio?

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.